Navigation Links
Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
Date:12/10/2012

SEATTLE Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy, or FSHD, by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease. The protein activity is what damages muscle cells and leads to progressive muscle weakness and atrophy in FSHD patients.

The genetic and disease mechanisms of FSHD were discovered by an international team of scientists led by Stephen Tapscott, M.D., Ph.D., a member of the Fred Hutch Human Biology Division, in a series of studies published between 2010 and early 2012. Tapscott will lead the Fred Hutch work in the GSK collaboration.

The team's discoveries also have implications for developing cancer immunotherapies because researchers also discovered that DUX4 regulates cancer/testis antigens. Cancer/testis antigens are encoded by genes that are normally expressed only in the human germ line but are also abnormally expressed in various tumor types, including melanoma and carcinomas of the bladder, lung and liver. This knowledge will give researchers a way to manipulate the expression of cancer/testis antigens, potentially opening the opportunity to use these antigens in a cancer vaccine.

The partnership with GSK is a first of its kind for Fred Hutch, which is also the first U.S.-based institution to sign on with GSK's "Discovery Partnership with Academia" (DPAc) program. GSK launched the program last year to combine the insight and creativity of the academic world with GSK's drug-discovery expertise to turn innovative research into medicines that benefit patients.

GSK currently has DPAc collaborations in place with Cambridge University and the University of Dundee in the U.K.

Unlike traditional licensing agreements in which the licensee is given full control to develop a discovery, the collaboration will involve GSK and Fred Hutch scientists working together to develop, test and hopefully bring to market a clinical treatment.

"GSK has huge expertise in developing agents against protein activity, so our opportunity to work with them is fantastic," Tapscott said.

"At GSK we believe that combining our drug-discovery expertise with the in-depth disease knowledge of specialist academic groups can seed innovation and help speed up the discovery and development of new medicines," said Pearl Huang, global head of DPAc. "We're excited to be expanding our academic program in North America and are looking forward to working closely with scientists like Dr. Tapscott, whose deep understanding of disease biology will complement our own work in this field."

FSHD affects about one in 20,000 individuals and usually begins in late adolescence. The effects start around the facial and upper-extremity muscles and eventually progress to muscles in the lower extremity. People with more severe FSHD become wheelchair bound and their life spans are often shortened.

In an era of flat federal research funding, this collaboration signals an increasing interest on the part of Fred Hutch to develop partnerships that further its lifesaving and innovative research.

"We're looking for more creative academic-industry partnerships like this one between Fred Hutch and GSK," said Ulrich Mueller, vice president of industry relations and technology transfer at Fred Hutch.

Tapscott's research on FSHD, which provides the scientific basis for the collaboration with GSK, was funded by Friends of FSH Research, the National Institute of Neurological Disorders and Stroke, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Financial terms of the Fred Hutch-GSK partnership were not disclosed.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related biology news :

1. Stem cell research provides hope for infertile cancer survivors
2. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
3. Clinical trial tests rice bran to prevent cancer
4. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
5. Predicting the age at menopause of women having suffered from childhood cancers
6. Research shows immune system response is detrimental to novel brain cancer therapy
7. University of Tennessee researchers find fungus has cancer-fighting power
8. Newly discovered effects of vitamin D on cancer
9. Fruit fly studies guide investigators to misregulated mechanism in human cancers
10. Does your job increase your breast cancer risk?
11. Reconsidering cancers bad guy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
Breaking Biology Technology: